2020
DOI: 10.1186/s13046-020-01785-7
|View full text |Cite
|
Sign up to set email alerts
|

Loss of miR-192-5p initiates a hyperglycolysis and stemness positive feedback in hepatocellular carcinoma

Abstract: Background Emerging studies revealed that cancer stem cells (CSCs) possessed peculiar metabolic properties, which however remained largely unknown in hepatocellular carcinoma (HCC). Genetic silencing of liver-abundant miR-192-5p was a key feature for multiple groups of CSC-positive HCCs. We thus aimed to investigate essential metabolic features of hepatic CSCs via using HCCs with miR-192-5p silencing as a model. Methods Datasets from two independen… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 48 publications
(79 reference statements)
0
11
0
Order By: Relevance
“…PFKFB4 is a key glycolysis regulator which activates the rate-limiting enzyme phosphofructokinase-1 (PFK-1) in glycolysis via its product fructose-2,6-biphosphate and has been proposed recently as a potential oncogene in HCC ( Shen et al, 2021 ). Considering the significance of glycolysis in HCC malignancy ( Hu L. et al, 2019 ; Feng et al, 2020 ; Gu et al, 2020 ), we reckoned that LINC01572 might have a glycolysis-promoting potential via increase in the PFKFB4 level. In line with this notion, we found that LINC01572 knockdown significantly inhibited the glycolytic process, which was effectively reversed by PFKFB4 overexpression ( Figures 7A,C,E ), whereas LINC01572 overexpression promoted HCC glycolysis, and PFKFB4 silencing remarkably blunted this effect ( Figures 7B,D,F,H ).…”
Section: Resultsmentioning
confidence: 99%
“…PFKFB4 is a key glycolysis regulator which activates the rate-limiting enzyme phosphofructokinase-1 (PFK-1) in glycolysis via its product fructose-2,6-biphosphate and has been proposed recently as a potential oncogene in HCC ( Shen et al, 2021 ). Considering the significance of glycolysis in HCC malignancy ( Hu L. et al, 2019 ; Feng et al, 2020 ; Gu et al, 2020 ), we reckoned that LINC01572 might have a glycolysis-promoting potential via increase in the PFKFB4 level. In line with this notion, we found that LINC01572 knockdown significantly inhibited the glycolytic process, which was effectively reversed by PFKFB4 overexpression ( Figures 7A,C,E ), whereas LINC01572 overexpression promoted HCC glycolysis, and PFKFB4 silencing remarkably blunted this effect ( Figures 7B,D,F,H ).…”
Section: Resultsmentioning
confidence: 99%
“…Multiple hepatic CSC biomarkers have already been identified. In this study, we have added a genetic signature of these liver CSCs and revealed the signaling pathways that regulate HCC[ 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…In addition, it has also been widely reported that miRNAs play an important role in dominating the EMT and stemness of HCC [ 2 , 26 ]. For example, miR-192-5p and miR-568 were found to regulate the stemness behavior to affect HCC progression [ 27 , 28 ]. In our study, we found for the first time that miR-1275 can be positively regulated by genistein in HCC cells through transcriptome sequencing and series experiments.…”
Section: Discussionmentioning
confidence: 99%